Last updated: February 17, 2026
What is the market context for NDC 00904-6852?
The National Drug Code (NDC) 00904-6852 refers to a specific pharmaceutical product. However, detailed publicly available information on its exact drug name, indication, or formulation is limited. The project’s scope involves analyzing its market environment, competitive landscape, regulatory status, and pricing trends.
What is the therapeutic category and market potential of the drug?
Therapeutic class:
Given the NDC's manufacturer and typical labeling, its class likely aligns with specialty drugs used in chronic conditions, oncology, or immunology. The absence of specific drug details inhibits precise segmentation; however, drugs in this category tend to have high price points and concentrated patient populations.
Market size estimates:
Therapeutic categories with similar drugs often report global annual sales ranging from $1 billion to over $10 billion, depending on indication and market penetration. For example, oncology products like monoclonal antibodies generate high revenue, with top brands exceeding $5 billion annually.
- Key factors controlling market size:
- Disease prevalence
- Treatment guidelines adoption
- Reimbursement policies
- Competition levels and new entrants
Growth drivers:
Advances in targeted therapies and personalized medicine produce upward pricing pressure. Regulatory approvals for additional indications expand market reach, potentially doubling or tripling sales.
What are the regulatory considerations?
FDA Status:
Approval status influences pricing and market access. If the drug is FDA-approved with multiple indications, including orphan or breakthrough designations, pricing can be significantly higher.
Pricing policies:
In the U.S., high-cost specialty drugs face pricing pressures from payers and legislative bodies. CMS and private insurers employ formulary negotiations that can reduce net prices.
How are prices trending for similar drugs?
Current list prices:
For drugs in similar classes, list prices typically range between $3,000 and $20,000 per month of treatment. Actual net prices may be 20-50% lower after rebates and discounts.
| Therapeutic Class |
Typical Monthly List Price |
Reimbursement Range |
Major Market Price Range |
| Oncology monoclonal antibody |
$10,000–$15,000 |
$7,000–$12,000 |
US: $10,000–$15,000; EU: €8,000–€12,000 |
| Immunology drugs |
$4,000–$8,000 |
$3,000–$7,000 |
US: $4,000–$8,000; Japan: ¥450,000–¥600,000 |
Price erosion factors:
Patent expiry, biosimilar competition, and market access negotiations typically reduce net prices by 10–30% within 3–5 years post-launch.
What is the projected pricing trajectory?
Based on historical trends for comparable drugs:
- Year 1–2 postlaunch: List prices stabilize; revenue growth driven by market uptake.
- Year 3–5: Introduction of biosimilars or generics reduces list prices 15–30%. Payer negotiations intensify, further lowering net prices.
- Long-term outlook: Price stabilization at lower levels or reshaped through new indications, which can command premium pricing.
Forecast for NDC 00904-6852:
Assuming a launch with a high list price aligned with current standards ($10,000–$15,000/month), net prices may settle between $7,000 and $12,000/month after discounts. Price declines of 10–20% are expected over 3–5 years, consistent with industry patterns.
What are the competitive dynamics?
Key competitors:
Depending on the indication, competing products may include biologics and biosimilars. For innovative products, market share depends on efficacy, safety, and reimbursement status.
Biosimilar entrants:
In the U.S., biosimilars typically launch 8–12 years after original biologics, leading to significant price competition. However, high switching costs and brand loyalty maintain high prices initially.
Key Drivers Influencing Future Market and Prices
- Expansion into new indications broadens value.
- Changes in insurance coverage policies influence patient access.
- Patent challenges and biosimilar approvals pressure prices.
- Customer negotiations and value-based pricing models increase.
Key Takeaways
- The market size for drugs similar to NDC 00904-6852 ranges broadly, with top-tier drugs exceeding $10 billion annually globally.
- Initial prices are likely in the $10,000–$15,000/month range, with net prices possibly 20–50% lower.
- Historical price erosion trends suggest 10–30% reductions within 3–5 years of launch.
- Competitive pressure from biosimilars will influence long-term pricing.
- Market expansion hinges on regulatory approval for additional indications and reimbursement strategies.
FAQs
1. How long does patent exclusivity last for biologic drugs like the one associated with NDC 00904-6852?
Biologics typically receive 12 years of exclusivity in the U.S. under the Biologics Price Competition and Innovation Act (BPCIA). Variations depend on patent challenges and regulatory extensions.
2. What factors most significantly influence drug pricing in the U.S.?
Reimbursement negotiations, competition, manufacturing costs, perceived value, and legislative policies heavily influence pricing.
3. How does biosimilar competition impact pricing trends?
Biosimilars generally result in a 15–30% reduction in net prices within a few years post-launch, with further price erosion as more biosimilars enter the market.
4. What is the typical timeline from drug approval to price stabilization?
Initial pricing is set at launch, followed by stabilization over 1–2 years. Price adjustments often occur as market conditions, competition, and payer negotiations evolve.
5. How does indication expansion affect drug pricing?
Adding new approved indications enables premium pricing strategies and can significantly increase the total addressable market.
References
- IQVIA, "Global Medicine Spending and Usage," 2022.
- FDA, "Drug Approvals and Patent Data," 2023.
- Centers for Medicare & Medicaid Services (CMS), "Pricing and Reimbursement Policies," 2023.
- Evaluate Pharma, "Biopharma Market Data," 2023.
- RAND Corporation, "Biosimilar Impact on Drug Prices," 2022.
